Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd. develops regenerative and aesthetic medicine technologies based on plant-derived recombinant human collagen, or rhCollagen. News about CLGN centers on its BioInk and 3D bioprinting portfolio, including Collink.3D and BioFlex, as well as medical aesthetics programs such as photocurable dermal filler technology and tissue-regeneration applications.
Company updates also cover operating and financial results, distribution expansion for rhCollagen and BioInk products, Vergenix STR commercialization, intellectual-property activity, collaboration developments, capital actions and Nasdaq listing-compliance matters.
CollPlant Biotechnologies (NASDAQ: CLGN) reported a transformative 2020, with unaudited revenues of approximately $6 million, a 160% increase from 2019. The advancements stemmed from strategic collaborations, including partnerships with Allergan and United Therapeutics. Notably, Allergan's agreement utilizes CollPlant's recombinant human collagen for aesthetic applications, while the expanded deal with United Therapeutics addresses organ transplant shortages. The company maintains robust cash reserves of $50 million and no debt, reinforcing its growth potential as it enhances its regenerative medicine pipeline.
CollPlant Biotechnologies (NASDAQ:CLGN) has successfully closed a registered direct offering of 2,000,000 American Depositary Shares (ADSs) priced at $17.50 each, raising gross proceeds of $35.0 million. The funds will be utilized for general corporate purposes, including working capital and the development of regenerative and aesthetic medicine products. The offering is conducted under a shelf registration statement filed with the SEC. H.C. Wainwright & Co. served as the exclusive placement agent for this offering.
CollPlant Biotechnologies (NASDAQ:CLGN) announced a registered direct offering of 2,000,000 American Depositary Shares (ADSs) at $17.50 each, aiming to raise approximately $35 million in gross proceeds. The offering is expected to close around February 17, 2021. The net proceeds will support general corporate purposes, including working capital and the development of regenerative medicine products. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
CollPlant Biotechnologies (NASDAQ: CLGN) has secured a worldwide exclusive development and commercialization agreement with Allergan Aesthetics, part of AbbVie, for dermal and soft tissue filler products. This agreement includes an upfront payment of $14 million and potential milestone payments of up to $89 million. Allergan will utilize CollPlant's plant-derived recombinant human collagen (rhCollagen) alongside its own technologies. CEO Yehiel Tal expressed optimism for a transformative partnership, targeting a market expected to reach $10 billion by 2026.
CollPlant (NASDAQ: CLGN) has entered into a product manufacturing and supply agreement with STEMCELL Technologies, Canada's largest biotechnology company. This partnership involves the sale of CollPlant's recombinant human Type I collagen (rhCollagen) for use in cell culture media kits developed by STEMCELL. This agreement builds on their existing business relationship since 2014, aiming to enhance regenerative medicine research. STEMCELL's global distribution of these kits is expected to advance applications in stem cells, cancer, and cellular therapy.
CollPlant (NASDAQ: CLGN) reported a remarkable 511% increase in revenues for Q3 2020, totaling $4.1 million, up from $679,000 in Q3 2019. The company's comprehensive income reached $703,000 on a GAAP basis, or $1.1 million non-GAAP, significantly improving from a loss of $3.2 million in the same quarter last year. Cash and equivalents stood at $5.0 million. The strong financial performance is attributed to the collaboration with United Therapeutics and advancements in medical aesthetics.
CollPlant (NASDAQ: CLGN) announced the early development of an antiviral agent utilizing its recombinant human type I collagen (rhCollagen) embedded with silver nanoparticles (AgNP) for potential COVID-19 treatment. Initial in-vitro results show significant inhibition of avian coronavirus infectivity, a model for SARS-CoV-2. The company plans to develop an inhalation formulation aimed at protecting respiratory systems, which could help reduce transmission and severity of COVID-19.
CollPlant (NASDAQ: CLGN), a regenerative medicine company, announced a significant first order for its Vergenix Flowable Gel product in Ukraine, amounting to hundreds of thousands of dollars. The order comes from a new Russian-based distributor and will see shipments start in the current quarter. This follows a recent distribution agreement covering six Commonwealth of Independent States countries. Vergenix FG is designed for treating difficult wounds, enhancing patient care in Ukraine.
CollPlant (NASDAQ: CLGN) presented its plant-derived recombinant human collagen (rhCollagen) technology at the Science of Aging Virtual Symposium 2020. Dr. Nadav Orr discussed its applications in anti-aging therapies, highlighting the company's Skin Rejuvenation and Breast Implant pipelines. Data showed that a combination of rhCollagen and hyaluronic acid significantly enhanced the proliferation of normal human dermal fibroblasts after an 8-day treatment. The company is also focused on 3D bioprinting and has strategic partnerships with United Therapeutics and 3D Systems for developing innovative medical applications.
CollPlant (NASDAQ: CLGN) has announced a five-year distribution agreement for its Vergenix™ Flowable Gel in six CIS countries, including Belarus and Kazakhstan. The agreement includes an initial order worth hundreds of thousands of U.S. dollars. The gel is approved in Europe and is designed for treating acute and chronic wounds. A recent peer-reviewed study has shown excellent clinical outcomes for Vergenix™ FG. The company aims to expand its market presence and continue developing innovative applications for its rhCollagen technology.